KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Operating Expenses (2017 - 2025)

Biomarin Pharmaceutical's Operating Expenses history spans 16 years, with the latest figure at $919.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 56.88% year-over-year to $919.2 million, compared with a TTM value of $2.8 billion through Dec 2025, up 18.66%, and an annual FY2025 reading of $2.8 billion, up 18.66% over the prior year.
  • Operating Expenses for Q4 2025 was $919.2 million at Biomarin Pharmaceutical, up from $822.8 million in the prior quarter.
  • The five-year high for Operating Expenses was $919.2 million in Q4 2025, with the low at $382.0 million in Q1 2022.
  • Average Operating Expenses over 5 years is $563.9 million, with a median of $541.3 million recorded in 2023.
  • Year-over-year, Operating Expenses dropped 17.12% in 2022 and then soared 56.88% in 2025.
  • Tracing BMRN's Operating Expenses over 5 years: stood at $515.7 million in 2021, then rose by 6.77% to $550.6 million in 2022, then increased by 12.4% to $618.9 million in 2023, then decreased by 5.34% to $585.9 million in 2024, then soared by 56.88% to $919.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Operating Expenses are $919.2 million (Q4 2025), $822.8 million (Q3 2025), and $548.5 million (Q2 2025).